Browsing: Antibiotics

Antimicrobial Resistance This image shows a mixture of pills and medicines

ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.

1 2 3 4 11